The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

International Journal of Cancer, Wiley, ISSN 0020-7136

Volume 139, 10, 2016

DOI:10.1002/ijc.30291, Dimensions: pub.1043761060, PMID: 27464352,



  1. (1) Department of Medicine Herlev and Gentofte Hospital, Copenhagen University Hospital Denmark
  2. (2) Department of Oncology Herlev and Gentofte Hospital, Copenhagen University Hospital Denmark
  3. (3) Department of Surgical Gastroenterology and Transplantation Rigshospitalet, Copenhagen University Hospital Denmark
  4. (4) Danish Cancer Society Research Center, Danish Cancer Society Denmark
  5. (5) Department of General Visceral, and Transplant Surgery, University of Heidelberg Germany
  6. (6) Odense University Hospital Germany
  7. (7) Department of Oncology Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital Denmark
  8. (8) Department of Clinical Immunology Aalborg University Hospital Denmark
  9. (9) Copenhagen University Hospital, grid.4973.9, Capital Region






Biomarkers for early diagnosis of patients with pancreatic cancer (PC) are needed. Our aim was to identify panels of miRNAs in serum in combination with CA 19-9 for use in the diagnosis of PC. Four hundred seventeen patients with PC were included prospectively from Denmark (n = 306) and Germany (n = 111). Controls included 59 patients with chronic pancreatitis (CP) and 248 healthy subjects (HS). MiRNAs were analyzed in pretreatment serum samples from 3 cohorts: discovery cohort (754 human miRNAs, TaqMan(®) Human MicroRNA assay, Applied Biosystem; PC n = 133, controls n = 72); training cohort (34 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 198, controls n = 184); validation cohort (13 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 86, controls n = 51). We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p). Diagnostic accuracy of detecting PC in the training cohort was AUC (Index I 0.85; II 0.87; III 0.85; IV 0.95; CA 19-9 0.93); specificity (I 0.71; II 0.76; III 0.66; IV 0.90 (fixed sensitivity at 0.85); CA 19-9 0.93). Combining serum CA 19-9 and Index II best discriminated Stages I and II PC from HS [AUC 0.93 (0.90-0.96), sensitivity 0.77 (0.69-0.84), specificity 0.94 (0.90-0.96) and accuracy 0.88 (0.84-0.91)]. In conclusion, we identified four diagnostic panels based on 5 or 12 miRNAs in serum that could distinguish patients with PC from HS and CP.


Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

Aalborg University

Danish Open Access Indicator

2016: Unused

Research area: Medicine

Danish Bibliometrics Indicator

2016: Level 1

Research area: Medicine

Dimensions Citation Indicators

Times Cited: 15

Field Citation Ratio (FCR): 3.88

Relative Citation ratio (RCR): 0.57